Steffan Vartanian

TL;DR: Deep whole-genome sequencing and transcriptome sequencing on 19 lung cancer cell lines and three lung tumor/normal pairs show that cell line models exhibit similar mutation spectra to human tumor samples, and demonstrate that cancer-specific alternative splicing is a widespread phenomenon that has potential utility as therapeutic biomarkers.

TL;DR: The data show that the activity of brusatol is not restricted to Nrf2 but, rather, functions as a global protein synthesis inhibitor and induces its potent cellular cytotoxicity effects on multiple cancer cell lines in a manner independent of KEAP1/Nrf2 activity and with a profile similar to the protein translation inhibitor silvestrol.

TL;DR: It is concluded that there are conserved components of mutant K-Ras signaling and phenotypes but that many depend on cell context and environmental cues.

TL;DR: It is demonstrated that the WT copies of HRas, NRas and KRas play unique roles in the context of mutant KRas-driven tumours.

TL;DR: The functional data coupled with the restricted normal tissue distribution of testisin and its overexpression in a majority of ovarian cancers validates this cell surface protein as a target for therapeutic intervention.